Financial Analysis
Filing-based analysis. Market pricing is not included. Fundamentals from SEC filings; economic data from FRED and the BLS. About our data
Filing evidence summary
Mixed evidenceCoverage 5/5 core metricsFlagged areas: Dilution.
Backward-looking filed evidence under visible rules - not a rating, forecast or investment advice. Missing data is never scored.
Evidence signals
- 1 filing risk check flagged
Flagged areas: Dilution.
Why this surfaced
The full financial analysis shows each value, threshold, and sector limitation.
- Revenue expanded
Latest reported annual revenue changed +100.0% from the prior reported annual observation.
Why this surfaced
Direction threshold: above +2% constructive; below -2% caution; otherwise monitor. This is not labeled one-year growth when filing periods have a gap. Period end 2025-12-31.
- Operating margin improved
Operating margin changed +36.2 percentage points from the prior annual period.
Why this surfaced
Direction threshold: more than +1 percentage point constructive; below -1 point caution. Period end 2025-12-31.
- Free cash flow turned positive
Latest reported free cash flow was $16M.
Why this surfaced
Free cash flow = operating cash flow minus capital expenditures; positive is supporting evidence, not a valuation conclusion. Period end 2025-12-31.
Core trend metrics
Hover a tile for its exact definition; the Statements tab carries per-cell filing citations.
Where to look next
Risk checks
- Dilution
Financial movement
- Cash→ flat
- Long-term debt→ flat
- Inventory→ flat
- Receivables→ flat
- Current assets→ flat
Source & freshness
- Source
- SEC EDGAR XBRL
- Fetched
- 2026-09-06
- Latest period end
- 2025-12-31
- Filings
- EDGAR ↗
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Prenatal$277M90.8%+89.9% yoy
- Oncology$25M8.2%+747.6% yoy
- Clinical Trial Support And Other Services$3.05M1.0%-18.3% yoy
Members sum to the consolidated $305M for this period.
- Prenatal$96.5M89.1%+72.1% yoy
- Oncology$10.7M9.9%+392.4% yoy
- Clinical Trial Support And Other Services$1.14M1.1%+61.0% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
Peer percentiles
latest fiscal year ending 2025-12-31 · among 3,990 US-listed filers · 316 in Healthcare| Metric | Value | vs all filers | vs sector |
|---|---|---|---|
Revenue latest fiscal-year revenue as filed | $305M | 38thof 3,301 middle third | 50thof 291 middle third |
Revenue growth latest fiscal-year revenue vs the prior fiscal year | 100.0% | 94thof 3,137 top third | 98thof 277 top third |
Gross margin gross profit ÷ revenue | 68.3% | 83rdof 1,603 top third | 75thof 212 top third |
Operating margin operating income ÷ revenue | 5.3% | 57thof 2,819 middle third | 64thof 280 middle third |
Net margin net income ÷ revenue | 2.4% | 50thof 3,263 middle third | 63rdof 290 middle third |
Free-cash-flow margin (operating cash flow − |capex|) ÷ revenue | 5.2% | 52ndof 2,679 middle third | 60thof 261 middle third |
Return on equity net income ÷ stockholders' equity (positive equity only) | 1.6% | 45thof 3,576 middle third | 61stof 291 middle third |
Stock comp ÷ revenue stock-based compensation ÷ revenue · lower is ranked higher | 5.2% | 34thof 2,895 middle third | 40thof 272 middle third |
Days sales outstanding receivables ÷ revenue × 365 · lower is ranked higher | 50 days | 50thof 2,398 middle third | 63rdof 266 middle third |
Net debt ÷ operating cash flow net debt ÷ operating cash flow (OCF > 0) · lower is ranked higher | -17.8× | 100thof 1,546 top third | 100thof 116 top third |
Cash conversion operating cash flow ÷ net income (net income > 0) | 3.3× | 86thof 1,118 top third | 91stof 75 top third |
Cash-flow accrual ratio (net income − operating cash flow) ÷ average total assets · lower is ranked higher | -3.7% | 45thof 1,333 middle third | 43rdof 92 middle third |
Balance-sheet accrual ratio change in net operating assets ÷ average net operating assets · lower is ranked higher | 39.4% | 13thof 1,073 bottom third | 9thof 75 bottom third |
Each filer's latest fiscal year as stored by the nightly crawl; fiscal year ends differ across the universe. A metric ranks only filers for which it is computable from filed facts. Ties split; a rank reads "better than N% of filers" in the metric's own direction. Descriptive and educational, not a rating.
Earnings quality
latest fiscal year ending 2025-12-31 · accruals and cash conversion as filedPer fiscal year from filed facts: cash conversion = operating cash flow / net income (net income > 0); cash-flow accrual ratio = (net income - operating cash flow) / average total assets; balance-sheet accrual ratio = change in net operating assets / average net operating assets, NOA = (assets - cash) - (liabilities - debt). Descriptive; a missing input yields a missing ratio. High accrual ratios and cash conversion well below one are the measures the accruals literature associates with less persistent earnings; they are screens to read the cash-flow statement with, not conclusions. The per-year series is part of Pro risk analysis.
Point-in-time ledger
first-reported vs latest filing · periods since 2020-01-01 · 0 changed periodsNo period on file has changed between its first report and the latest filing carrying it.
First filing reporting each period vs the latest filing carrying it (10-K and 10-Q only, periods since 2020, the extractor's winning tag per concept); a change under 0.5% is treated as rounding. A change can be a restatement, a reclassification or a re-tagging in a later comparative column; the two filings are linked so the reader can see which. Descriptive, not a verdict.
Notes by disclosure type
debt, leases, revenue, segments, contingencies, taxes and more · the filer's own wordsCommitments and contingencies · 1,942 characters as filed
Commitments and Contingencies Legal Proceedings From time to time, the Company is party to certain claims in the ordinary course of business. The Company, in conjunction with its legal counsel, assesses the need to record a liability for litigation or contingencies. A liability is recorded when and if it is determined that such a liability for litigation or contingencies is both probable and the amount can be reasonably estimated. The Company believes that it is not presently a party to any litigation of which the outcome, if determined adversely, would individually or in the aggregate be expected to have a material and adverse effect on the business, operating results, cash flows, or financial position. Legal fees are expensed in the period in which they are incurred. Indemnification Agreements The Company has entered into indemnification agreements with its directors and officers against any liabilities that may arise by reason of their status or service as directors or officers, other than liabilities arising from willful misconduct of the individual. Additionally, in the ordinary course of business, the Company enters into agreements of varying scope and terms pursuant to which it agrees to indemnify customers, vendors, lessors, business partners, and other parties with respect to certain matters, including, but not limited to, losses arising out of the breach of such agreements, services to be provided by the Company, or from intellectual property infringement claims mad …
CommitmentsAndContingenciesDisclosureTextBlock · excerpt; the full note is in the filing
Fair value · 7,227 characters as filed
Fair Value Measurements The fair value measurements of assets and liabilities that are measured at fair value on a recurring basis consisted of the following as of September 30, 2025 (in thousands): As of September 30, 2025 Level 1 Level 2 Level 3 Total Current assets: Money market funds $ 7,770 $ - $ - $ 7,770 Total assets $ 7,770 $ - $ - $ 7,770 Liabilities: Redeemable convertible preferred stock warrants $ - $ - $ 406 $ 406 Common stock warrants - - 3,942 3,942 Term loan - - 54,986 54,986 Total liabilities $ - $ - $ 59,334 $ 59,334 The fair value measurements of assets and liabilities that are measured at fair value on a recurring basis consisted of the following as of December 31, 2024 (in thousands): As of December 31, 2024 Level 1 Level 2 Level 3 Total Current assets: Money market funds $ 7,538 $ - $ - $ 7,538 Total assets $ 7,538 $ - $ - $ 7,538 Liabilities: Redeemable convertible preferred stock warrants $ - $ - $ 230 $ 230 Common stock warrants - - 2,533 2,533 Term loan - - 51,481 51,481 Total liabilities $ - $ - $ 54,244 $ 54,244 Level 3 instruments consist of the Companys Series A-6 redeemable convertible preferred stock warrant liabilities, common stock warrant liabilities, a term loan and convertible notes. The fair values of the Series A-6 redeemable convertible preferred stock warrant and common stock warrant are measured using a probability weighted option pricing model. The significant assumptions used in preparing the option pricing model for valuing the com …
FairValueDisclosuresTextBlock · excerpt; the full note is in the filing
Income taxes · 1,850 characters as filed
Income Taxes The Company has an effective tax rate of (2.31)%, 0.15%, (1.03)% and (0.05)% for the three and nine months ended September 30, 2025 and 2024, respectively. The Company has historically incurred U.S. operating losses prior to the nine months ended September 30, 2025 and has minimal profits in its foreign jurisdictions. The Company updates its estimate of the annual effective tax rate each quarter and makes a cumulative adjustment in such period. The Company recorded immaterial amounts for the three and nine months ended September 30, 2025 and 2024, respectively. Income tax expense (benefit) consists primarily of income taxes for U.S. federal and the states in which the Company conducts business. Due to the Companys history of losses in the United States, a full valuation allowance on substantially all of the Companys deferred tax assets, including net operating loss carryforwards, research and development tax credits, and other book versus tax differences, was maintained. On July 4, 2025, the One Big Beautiful Bill Act (OBBBA) was enacted in the U.S. The OBBBA includes significant provisions, such as the permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act, modifications to the international tax framework and the restoration of favorable tax treatment for certain business provisions. The legislation has multiple effective dates, with certain provisions effective in 2025 and others implemented through 2027. The enactment of the OBBBA did …
IncomeTaxDisclosureTextBlock · excerpt; the full note is in the filing
Long-term debt · 10,456 characters as filed
Convertible Notes In September 2022, the Company entered into a Note Purchase Agreement for unsecured Convertible Promissory Notes (the Notes) to several note holders (the Note Holders) with a principal sum of $30.0 million together with interest thereon from the date of the Notes. The Notes accrue interest at a rate of 8.0% per annum, simple interest. The Notes were scheduled to mature on September 20, 2024, and the Company may not make prepayments without written consent of the majority Note holders. During May 2024, concurrent with the issuance of Series D redeemable convertible preferred stock, and pursuant to negotiation with the Note Holders, the Company and Note Holders agreed to settle the Notes through the issuance of Series C-1 redeemable convertible preferred stock to the Note Holders instead of Series D redeemable convertible preferred stock. The Notes converted into an aggregate of 1,726,823 shares of Series C-1 redeemable convertible preferred stock at a conversion price of approximately $19.6143 per share. The change in terms of the Notes was accounted for as a debt extinguishment as the settlement was not pursuant to the original conversion terms. Immediately prior to the extinguishment, the Company recorded a mark-to-market adjustment for the Notes resulting in a loss of $0.8 million for the nine months ended September 30, 2024 which was recorded to change in fair value of convertible notes in the Companys statements of operations and comprehensive income (lo …
LongTermDebtTextBlock · excerpt; the full note is in the filing
New accounting pronouncements · 4,640 characters as filed
In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (ASU 2023-09), which expands income tax disclosure requirements to include additional information related to the rate reconciliation of effective tax rates to statutory rates, as well as additional disaggregation of taxes paid. This ASU also removed disclosure related to certain unrecognized tax benefits and deferred taxes. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024. This ASU may be applied prospectively or retrospectively, and early adoption is permitted. The Company is currently evaluating this ASU to determine the impact it may have on its financial statements and related disclosures. In November 2024, the FASB issued ASU 2024-04, Debt Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments. This ASU clarifies guidance on the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion or extinguishment. This guidance is effective for the Company beginning on January 1, 2026, and early adoption is permitted, although the Company does not plan to early adopt. The Company is currently evaluating the impact of the adoption of this standard on the Companys financial statement disclosures. In November 2024 and January 2025, the FASB issued ASU 2024-03 and ASU 2025-01, respectively, Income StatementReporting …
NewAccountingPronouncementsPolicyPolicyTextBlock · excerpt; the full note is in the filing
Pensions and post-retirement benefits · 487 characters as filed
Employee Benefit Plan The Company sponsors a qualified 401(k) defined contribution plan covering eligible employees. Participants may contribute a portion of their annual compensation limited to a maximum annual amount set by the Internal Revenue Service. Employer contributions to the plan are discretionary. During the three and nine months ended September 30, 2025 and 2024, the Company contributed $0.9 million, $0.6 million, $2.6 million and $1.7 million to this plan, respectively.
PensionAndOtherPostretirementBenefitsDisclosureTextBlock
Related parties · 340 characters as filed
Related Party Transactions In February 2024, the Company repurchased 26,750 shares of common stock that were held by the former CFO. Please refer to Note 9 for additional information on this transaction. There were no other material related party transactions during the three months ended and nine months ended September 30, 2025 and 2024.
RelatedPartyTransactionsDisclosureTextBlock
Significant accounting policies · 21,060 characters as filed
Summary of Significant Accounting Policies Basis of Presentation The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (U.S. GAAP). Prior to April 2024, the financial statements also included the Companys wholly owned subsidiary SeqIndia Labs Private Limited which had immaterial activities and was not material to these financial statements and was divested in April 2024. All intercompany transactions and balances have been eliminated upon consolidation. The unaudited interim financial statements should be read in conjunction with the audited financial statements and the related notes thereto as of and for the year ended December 31, 2024, included in the Company's prospectus filed with the SEC pursuant to Rule 424(b) under the Securities Act of 1933, as amended, on November 6, 2025 (the Final Prospectus). For a summary of the Companys significant accounting policies refer to Note 2. Summary of Significant Accounting Policies in the notes to the financial statements as of and for the year ended December 31, 2024 included in the Final Prospectus. There have been no significant changes to these policies during the nine months ended September 30, 2025. Unaudited interim financial information The unaudited financial statements do not include all disclosures, including certain notes required by GAAP on an annual reporting basis. The unaudited interim financial statements have been prepare …
SignificantAccountingPoliciesTextBlock · excerpt; the full note is in the filing
Stockholders' equity · 8,207 characters as filed
Redeemable Convertible Preferred Stock As of September 30, 2025 and December 31, 2024, redeemable convertible preferred stock consisted of the following (in thousands, except for share data): Shares Authorized Shares Issued and Outstanding Net Carrying Value Aggregate Liquidation Preference Series A-1 1,349,650 1,349,650 $ 3,493 $ 540 Series A-2 1,137,210 1,137,210 2,943 910 Series A-3 899,730 899,730 2,328 900 Series A-4 25,761 25,761 67 50 Series A-5 114,613 114,613 297 100 Series A-6 5,805,861 5,796,201 14,999 15,000 Series B-1 5,182,287 5,182,287 54,889 55,000 Series B-2 2,566,902 2,566,902 27,243 16,025 Series C 6,079,919 5,628,825 143,268 143,500 Series C-1 1,726,823 1,726,823 39,886 33,870 Series D 4,656,233 4,656,233 129,996 156,563 Total 29,544,989 29,084,235 $ 419,409 $ 422,458 Common Stock As of September 30, 2025 and December 31, 2024, the Companys Certificate of Incorporation, as amended, authorized the Company to issue 51,100,000 shares of common stock with a par value of $0.00001. Total common stock outstanding as of September 30, 2025 and December 31, 2024 was 11,178,467 and 10,925,950, respectively. Each share of common stock is entitled to one vote. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when and if declared by the Board of Directors, subject to the prior rights of holders of all series of stock outstanding. No dividends have been declared or paid by the Company since inception. The Company …
StockholdersEquityNoteDisclosureTextBlock · excerpt; the full note is in the filing
Subsequent events · 3,261 characters as filed
Subsequent Events On November 7, 2025, the Company closed its initial public offering (the IPO) of 5,233,765 shares of its Class A common stock, which includes the exercise in full by the underwriters of their option to purchase from the Company 682,665 shares of the Companys Class A common stock, at a price to the public of $60.00 per share. The gross proceeds to the Company from the IPO were $314.0 million and the net proceeds amounted to $286.4 million, after deducting underwriting discounts and commissions and offering expenses payable by the Company. Immediately prior to the closing of the IPO, each outstanding share of the Companys Series A-1, Series A-2, Series A-3, Series A-4, Series A-5, Series A-6, Series B-1, Series B-2, Series C, Series C-1 and Series D redeemable convertible preferred stock converted, on a one-for-one basis, into 29,084,235 shares of the Companys Class A common stock (the conversion, the Reclassification). Following the Reclassification, and immediately prior to the closing of the IPO, 2,325,108 shares of Class A common stock held by Oguzhan Atay, our Chief Executive Officer and Co-Founder, and 2,227,542 shares of Class A common stock held by David Tsao, our Chief Technology Officer and Co-Founder, were exchanged at a 1:1 ratio for shares of Class B common stock. In connection with the IPO, the Companys Board of Directors adopted, and its stockholders approved, the 2025 Equity Incentive Plan (the 2025 Plan), which became effective on November 5, …
SubsequentEventsTextBlock · excerpt; the full note is in the filing
Source: SEC DERA Financial Statement and Notes data sets (txt.tsv), excerpts of the filer's own note text; the full note is in the linked filing. Excerpts are the first part of each note exactly as tagged in the filing; open the filing for the full text and the tables. Descriptive and educational, not advice.
Fundamentals from SEC EDGAR. Scores, the DCF, and every model shown are educational analysis, not investment advice or price predictions.